Medtide Inc. (3880) Receives CSRC Filing Notice for H Share Full Circulation

Bulletin Express

02/05

Medtide Inc. announced that, following the acceptance of its H Share Full Circulation application by the China Securities Regulatory Commission (CSRC) on July 27, 2025, a filing notice was issued on February 5, 2026. According to the filing notice, the conversion and listing process may proceed, and if it is not completed within 12 months from the notice’s date, an updated filing with the CSRC will be required.

Details of the conversion and listing plan have not been finalized. The H Share Full Circulation, conversion, and listing remain subject to further procedural requirements by the CSRC, The Stock Exchange of Hong Kong Limited, and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1141129814"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141129814\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141129814?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141129814","market":"hk","top_or_hot":-1,"title":"Medtide Inc. (3880) Receives CSRC Filing Notice for H Share Full Circulation","media":"Bulletin Express","content":"<p>Medtide Inc. announced that, following the acceptance of its H Share Full Circulation application by the China Securities Regulatory Commission (CSRC) on July 27, 2025, a filing notice was issued on February 5, 2026. According to the filing notice, the conversion and listing process may proceed, and if it is not completed within 12 months from the notice’s date, an updated filing with the CSRC will be required.</p>\n<p>Details of the conversion and listing plan have not been finalized. The H Share Full Circulation, conversion, and listing remain subject to further procedural requirements by the CSRC, The Stock Exchange of Hong Kong Limited, and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medtide Inc. (3880) Receives CSRC Filing Notice for H Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedtide Inc. (3880) Receives CSRC Filing Notice for H Share Full Circulation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-02-05 20:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Medtide Inc. announced that, following the acceptance of its H Share Full Circulation application by the China Securities Regulatory Commission (CSRC) on July 27, 2025, a filing notice was issued on February 5, 2026. According to the filing notice, the conversion and listing process may proceed, and if it is not completed within 12 months from the notice’s date, an updated filing with the CSRC will be required.</p>\n<p>Details of the conversion and listing plan have not been finalized. The H Share Full Circulation, conversion, and listing remain subject to further procedural requirements by the CSRC, The Stock Exchange of Hong Kong Limited, and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03880","symbol_name":"泰德醫藥","start_time":0,"source_url":"","article_id":"1141129814","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141129814","pubTimestamp":1770293122,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Medtide Inc. announced that, following the acceptance of its H Share Full Circulation application by the China Securities Regulatory Commission (CSRC) on July 27, 2025, a filing notice was issued on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03880":"泰德医药"},"translate_title":"Medtide Inc.(3880)收到证监会H股全流通备案通知书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03880":1},"content_text":"Medtide Inc. announced that, following the acceptance of its H Share Full Circulation application by the China Securities Regulatory Commission (CSRC) on July 27, 2025, a filing notice was issued on February 5, 2026. According to the filing notice, the conversion and listing process may proceed, and if it is not completed within 12 months from the notice’s date, an updated filing with the CSRC will be required.\nDetails of the conversion and listing plan have not been finalized. The H Share Full Circulation, conversion, and listing remain subject to further procedural requirements by the CSRC, The Stock Exchange of Hong Kong Limited, and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}